Business Context and Reporting Period
Radiopharm Theranostics Limited, a foreign private issuer based in Australia, filed Form 6-K for the month of June 2026. The filing serves to disclose two public notices issued to the Australian Securities Exchange on June 30, 2026, regarding the cessation of trading for its securities (ticker: RAD) and the status of unquoted securities.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a regulatory disclosure of corporate actions rather than a financial statement.
Material Changes
- Cessation of Trading: The Company announced the cessation of its securities on the Australian Securities Exchange.
- Unquoted Status: The Company notified the market regarding the status of its unquoted securities.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the implications of the securities cessation. The document explicitly states that the report and its exhibits are not deemed "filed" for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into registration statements unless expressly stated.
Investor Verification Checklist
- Verify the specific reasons for the cessation of securities trading on the Australian Securities Exchange.
- Confirm the current status and tradability of unquoted RAD securities.
- Review the attached exhibits (99.1 and 99.2) for detailed terms regarding the cessation and unquoted status.
- Check for subsequent filings that may provide financial context or reasons for the delisting.